Metro, G., Addeo, A., Signorelli, D., Gili, A., Economopoulou, P., Roila, F., . . . Mountzios, G. (2019). Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: Real-world data from a European cohort. J Thorac Dis.
Styl ChicagoMetro, Giulio, et al. "Outcomes From Salvage Chemotherapy or Pembrolizumab Beyond Progression With or Without Local Ablative Therapies for Advanced Non-small Cell Lung Cancers With PD-L1 ≥50% Who Progress On First-line Immunotherapy: Real-world Data From a European Cohort." J Thorac Dis 2019.
Citace podle MLAMetro, Giulio, et al. "Outcomes From Salvage Chemotherapy or Pembrolizumab Beyond Progression With or Without Local Ablative Therapies for Advanced Non-small Cell Lung Cancers With PD-L1 ≥50% Who Progress On First-line Immunotherapy: Real-world Data From a European Cohort." J Thorac Dis 2019.